Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2022 14:14 ET | Source: Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media ReleaseCopenhagen, Denmark, February 16, 2022 Genmab filed Form 20-F for the financial year 2021 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...
February 16, 2022 11:00 ET | Source: Genmab A/S

Genmab Publishes 2021 Annual Report

Genmab Publishes 2021 Annual Report Company Announcement Copenhagen, Denmark; February 16, 2022 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2021. Below is a...
January 26, 2022 08:44 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; January 26, 2022 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
January 25, 2022 15:30 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 15,045 restricted stock units and 17,841...
January 25, 2022 06:30 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021

Company Announcement Net sales of DARZALEX® in 2021 totaled USD 6,023 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 25, 2022 –...
January 04, 2022 09:00 ET | Source: Genmab A/S

Genmab and Synaffix Enter into License Agreement for ADC Technology

Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...
January 03, 2022 18:38 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; January 4, 2022 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
January 03, 2022 07:19 ET | Source: Genmab A/S

Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; January 3, 2022Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 40th Annual J.P. Morgan...
December 14, 2021 13:06 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 14, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 15,541 shares as a consequence of the exercise of employee warrants. The...
December 13, 2021 03:28 ET | Source: Genmab A/S

Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base

Media ReleaseCopenhagen, Denmark, December 13, 2021 The European Commission has granted Janssen-Cilag International NV (Janssen) Conditional Marketing Authorization for RYBREVANT® (amivantamab) for...